CRISPR Therapeutics AG (CRSP) company profile
Close on Nov 17, 2026Market cap $3.88BP/E –Yield –
About CRISPR Therapeutics
Biological Products, (No Diagnostic Substances), SIC 2836
The company is a biopharmaceutical firm that develops gene-based medicines using CRISPR/Cas9 gene-editing technology. It operates across four primary areas: hemoglobinopathies, in vivo editing, CAR T cell therapies, and regenerative medicine. Its approved therapy, CASGEVY, co-developed with Vertex Pharmaceuticals, treats severe sickle cell disease and transfusion-dependent beta thalassemia. Other investigational candidates address cardiovascular conditions, autoimmune disorders, cancers, and Type 1 diabetes. Its end users are patients suffering from severe genetic, hematologic, oncologic, and metabolic diseases.
Its approved therapy is authorized in the United States, the European Union, Great Britain, Canada, Switzerland, and Middle Eastern countries including Saudi Arabia, Bahrain, Qatar, the United Arab Emirates, and Kuwait. The company operates a manufacturing facility in Framingham, Massachusetts, to produce investigational cell therapies, and engages in clinical collaborations across the United States and Greater China. The provided text does not state the location of the company's headquarters.
Summary of the business section of CRISPR Therapeutics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- CRISPR Therapeutics AG
- Founded
- 2013
- Headquarters
- Zug, Switzerland
- Address
- Baarerstrasse 14
- Phone
- (617) 315-4600
- Website
- www.crisprtx.com
- Employees
- 393, Dec 31, 2024
- Industry
- Biological Products, (No Diagnostic Substances)
- Incorporated in
- V8
- Fiscal year ends
- December 31
- Auditor
- Ernst & Young LLP, Boston, Massachusetts
Stock & identifiers
- Ticker
- CRSP
- Exchange
- Nasdaq
- IPO date
- Oct 19, 2016
- Shares outstanding
- 97M, Jul 31, 2026
- Public float
- $4.10B, Jun 30, 2025
- Filer category
- Large accelerated filer
- SEC CIK
- 1674416
- CUSIP
- H17182108
- FIGI
- BBG00DBBGRX1
- Share class FIGI
- BBG00DBBGRY0
- EIN
- 47-3173478
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Samarth Kulkarni | Chief Executive Officer, Director | 397,521 |
| Sivakesava Sakhamuri | Chief Technical Officer | – |
| Naimish Patel | Chief Medical Officer | 19,357 |
| James R. Kasinger | General Counsel and Secretary | 95,857 |
| Andrew Jacob Silver | Chief Financial Officer | – |
| Raju Prasad | Chief Financial Officer | 14,815 |
| Julianne Bruno | Chief Operating Officer | 17,632 |
| Simeon George | Director | 2,054,249 |
| Ali Behbahani | Director | 345 |
| John Greene | Director | 7,000 |
| Katherine A. High | Director | – |
| Douglas A. Treco | Director | 22,000 |
| Briggs Morrison | Director | 5,209 |
| Christian Rommel | Director | – |
| Sandesh Mahatme | Director | – |
| Maria Fardis | Director | – |
| Harold Edward Fleming | Director | – |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 | $7.68M | $21.97M | $3.60M | $34 | $120 |
| FY2024 | $33.18M | $10.02M | $5.59M | $65 | $114 |
| FY2023 | $12.32M | $24.81M | $2.61M | $103 | $115 |
| FY2022 | $20.73M | $1.73M | $3.86M | $67 | $111 |
| FY2021 | $17.04M | -$27.37M | $5.65M | $124 | $125 |
| FY2020 | $9.11M | $76.94M | $3.19M | $251 | $126 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Oct 19, 2016
- Offer price
- $14.00
- Securities offered
- 4,000,000
- Gross proceeds
- $56.00M
- Exchange
- Nasdaq
- First trading day
- Oct 19, 2016
- First-day close
- $14.09+0.6%
- Lock-up ends (est.)
- Apr 17, 2017
“The initial public offering price is $14.00 per common share.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“As of December 31, 2024, we had 393 full-time employees.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Dec 16, 2019 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Oct 19, 2016 | IPO | Initial public offering priced (424B4 prospectus) |
| Oct 18, 2016 | Listing | Registration of securities on an exchange (Form 8-A) |
See a number that looks wrong?